Breaking News Instant updates and real-time market news.

HUM

Humana

$297.46

-0.43 (-0.14%)

, INST

Instructure

$40.12

0.62 (1.57%)

10:17
08/12/19
08/12
10:17
08/12/19
10:17

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Humana (HUM) upgraded to Overweight from Neutral at Cantor Fitzgerald with analyst Steven Halper saying the company's Louisiana Medicaid contract award demonstrates its success outside Medicare. 2. Instructure (INST) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Schwartz saying he sees a good self-help story. 3. Apple Hospitality REIT (APLE) upgraded to Overweight from Equal Weight at Barclays with analyst Anthony Powell saying with "strong" cash returns, a lower mix of higher price urban markets, and higher mix of suburban and non-top 25 markets, Apple Hospitality offers exposure to "differentiated demand trends and relatively stable cash flows" within the lodging real estate investment trust subsector. 4. James Hardie (JHX) upgraded to Buy from Neutral at UBS. 5. Zimmer Biomet (ZBH) upgraded to Buy from Hold at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

HUM

Humana

$297.46

-0.43 (-0.14%)

INST

Instructure

$40.12

0.62 (1.57%)

APLE

Apple Hospitality REIT

$15.50

0.115 (0.75%)

JHX

James Hardie

$15.03

0.16 (1.08%)

ZBH

Zimmer Biomet

$138.47

0.06 (0.04%)

  • 12

    Aug

  • 04

    Sep

  • 09

    Sep

  • 12

    Sep

  • 13

    Nov

HUM Humana
$297.46

-0.43 (-0.14%)

08/05/19
WELS
08/05/19
NO CHANGE
WELS
Louisiana loss a 'surprising negative' for Centene, says Wells Fargo
Louisiana selected four managed care providers for its Medicaid contracts and the winners included Humana (HUM), UnitedHealth (UNH), AmeriHealth Caritas, and Community Care Health Plan/Healthy Blue, Wells Fargo analyst Peter Costa tells investors in a research note. The loss is a "surprising negative" for Centene (CNC), which also failed to get a statewide contract in North Carolina, says Costa. The analyst would not be surprised to see a protest filed by Centene and/or CVS Health (CVS), who was also not selected. He estimates Centene could lose about $2.4B in premiums and about 13c in earnings per share while CVS could lose about $600M in premiums or about 1c in earnings per share.
08/01/19
RHCO
08/01/19
NO CHANGE
Target $340
RHCO
Hold
Humana price target raised to $340 from $320 at SunTrust
SunTrust analyst David MacDonald raised his price target on Humana to $340 after its "superb" Q2 results on "noticeable" Medicare Advantage strength and "attractive" utilization trends. The analyst keeps his Hold rating however and sees risk-reward on the stock as balanced amid increased competition.
08/12/19
CANT
08/12/19
UPGRADE
Target $345
CANT
Overweight
Humana upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper upgraded Humana to Overweight from Neutral and raised his price target for the shares to $345 from $300. The company's Louisiana Medicaid contract award demonstrates its success outside Medicare, Halper tells investors in a research note. Further, the analyst believes Humana's investments in population health management and social determinants of health will accelerate its growth over time.
08/01/19
UBSW
08/01/19
NO CHANGE
Target $317
UBSW
Neutral
Humana price target raised to $317 from $266 at UBS
UBS analyst Whit Mayo raised his price target on Humana to $317 after its Q2 earnings beat driven by strong membership growth in Medicare Advantage and its "well controlled" trend in the retail segment. The analyst keeps his Neutral rating on the stock however, citing the management's maintained view that it will not reach its long-term growth target of 11%-15% in 2020 because of the "disproportionate" concentration in Medicare's high-premium product.
INST Instructure
$40.12

0.62 (1.57%)

08/12/19
08/12/19
UPGRADE

Outperform
Instructure upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Brian Schwartz upgraded Instructure to Outperform from Perform, with a $56 price target, as he sees a good self-help story. The analyst notes that investor sentiment has materially shifted away from expectations of unrealistically high growth rates many years into the future and the Street has finally accepted that a decelerating U.S. education spending trend cannot be easily overcome by robust growth Internationally and/or in the corporate business and actually hurts Instructure. Overall, he thinks valuation has reached an attractive level and the risk/reward is too attractive to ignore.
08/12/19
OPCO
08/12/19
UPGRADE
OPCO
Outperform
Instructure upgraded to Outperform from Perform at Oppenheimer
Oppenheimer analyst Brian Schwartz upgraded Instructure to Outperform from Perform with a $56 price target.
07/12/19
07/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Neutral from Buy at Citi. 2. Rexnord (RXN) was downgraded to Underperform from Buy at BofA/Merrill while Parker-Hannifin (PH) was downgraded to Neutral from Buy. 3. Instructure (INST) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Peterson saying his rating change "in no way reflects any incremental concerns about the company's strategic direction," but is entirely about his more cautious view on 2020 growth projections. 4. MSC Industrial (MSM) downgraded to Neutral from Buy at Northcoast with analyst Tom Hayes citing the company's report of weaker than expected organic sales growth and margin headwinds in Q3. 5. Charles Schwab (SCHW) was downgraded to Neutral from Buy at BofA/Merrill and to Market Perform from Outperform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/30/19
NEED
07/30/19
NO CHANGE
Target $46
NEED
Buy
Instructure price target lowered to $46 from $58 at Needham
Needham analyst Scott Berg lowered his price target on Instructure to $46, saying that while the company beat on Q2 earnings, its billings were in-line and its revenue growth excluding acquisitions impact decelerated to below 20%. The analyst maintains his Buy rating on Instructure shares however, noting that he remains optimistic about the company's GTM and Bridge product enhancement sentiment, which suggests that billings could recover in the back half of 2019.
APLE Apple Hospitality REIT
$15.50

0.115 (0.75%)

08/12/19
LEHM
08/12/19
UPGRADE
Target $18
LEHM
Overweight
Apple Hospitality REIT upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Anthony Powell upgraded Apple Hospitality REIT to Overweight from Equal Weight with an unchanged price target of $18.
08/12/19
LEHM
08/12/19
UPGRADE
Target $18
LEHM
Overweight
Barclays upgrades Apple Hospitality REIT on 'differentiated demand trends'
Barclays analyst Anthony Powell upgraded Apple Hospitality REIT to Overweight from Equal Weight with an unchanged price target of $18. With "strong" cash returns, a lower mix of higher price urban markets, and higher mix of suburban and non-top 25 markets, Apple Hospitality offers exposure to "differentiated demand trends and relatively stable cash flows" within the lodging real estate investment trust subsector, Powell tells investors in a research note. He views the current multiple and 7.8% yield as one of the more attractive entry points for the stock since his January 2018 initiation. The stock's outperformance could continue through at least year end, says the analyst.
06/25/19
SOCO
06/25/19
INITIATION
Target $27
SOCO
Equalweight
Apple Hospitality REIT initiated with an Equalweight at Capital One
Capital One initiated Apple Hospitality REIT with a Neutral and $27 price target.
JHX James Hardie
$15.03

0.16 (1.08%)

08/12/19
UBSW
08/12/19
UPGRADE
UBSW
Buy
James Hardie upgraded to Buy from Neutral at UBS
UBS upgraded James Hardie to Buy from Neutral and raised its price target for the shares to A$23.80 from A$19.90.
10/16/18
MSCO
10/16/18
UPGRADE
MSCO
Overweight
James Hardie upgraded to Overweight from Equal Weight at Morgan Stanley
05/20/19
UBSW
05/20/19
DOWNGRADE
UBSW
Neutral
James Hardie downgraded to Neutral from Buy at UBS
UBS downgraded James Hardie to Neutral from Buy and lowered its price target for the shares to A$19.60 from A$20.20.
05/21/19
LYON
05/21/19
DOWNGRADE
LYON
Outperform
James Hardie downgraded to Outperform from Buy at CLSA (pre-open)
ZBH Zimmer Biomet
$138.47

0.06 (0.04%)

08/12/19
ARGS
08/12/19
UPGRADE
ARGS
Buy
Zimmer Biomet upgraded to Buy from Hold at Argus
07/30/19
LEHM
07/30/19
UPGRADE
Target $140
LEHM
Equal Weight
Zimmer Biomet upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Kristen Stewart upgraded Zimmer Biomet Holdings to Equal Weight from Underweight and raised her price target for the shares to $140 from $117. The analyst sees her downside scenario as now less likely following the company's Q2 results.
07/29/19
BARD
07/29/19
UPGRADE
Target $154
BARD
Outperform
Zimmer Biomet upgraded to Outperform at Baird
As reported previously, Baird analyst Jeffrey Johnson upgraded Zimmer Biomet to Outperform from Neutral. The analyst upgrade comps following Q2 results as he was encouraged by its stabilizing top-line performances, its margin/cash flow implications of the improving revenue trends, and confidence in management's ability to deliver mid-single digit+ earnings and improved free cash flow over coming years. Johnson raised his price target to $154 from $132 on Zimmer Biomet shares.
07/29/19
OPCO
07/29/19
NO CHANGE
Target $150
OPCO
Outperform
Zimmer Biomet price target raised to $150 from $135 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Zimmer Biomet to $150 from $135 after the company reported Q2 EPS slightly ahead of consensus estimates and raised sales/EPS guidance for 2019 on the low end. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

CSOD

Cornerstone OnDemand

$51.34

0.32 (0.63%)

08:07
08/22/19
08/22
08:07
08/22/19
08:07
Hot Stocks
Cornerstone OnDemand announces $150M share repurchase program »

Cornerstone OnDemand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

GTEH

GenTech

$0.00

(0.00%)

08:06
08/22/19
08/22
08:06
08/22/19
08:06
Hot Stocks
GenTech announces accelerated plans for CBD-Infusion Cafe launch »

GenTech Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.04

0.08 (0.89%)

08:06
08/22/19
08/22
08:06
08/22/19
08:06
Hot Stocks
President of Changan Ford joint venture in China Nigel Harris to retire »

Ford announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

MBIO

Mustang Bio

$4.65

0.61 (15.10%)

08:05
08/22/19
08/22
08:05
08/22/19
08:05
Hot Stocks
Mustang Bio granted RMAT designation for MB-107 for XSCID »

Mustang Bio and St. Jude…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

LOW

Lowe's

$108.00

9.96 (10.16%)

08:04
08/22/19
08/22
08:04
08/22/19
08:04
Recommendations
Lowe's analyst commentary at Wedbush »

Lowe's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 20

    Nov

TRHC

Tabula Rasa HealthCare

$64.93

1.38 (2.17%)

08:03
08/22/19
08/22
08:03
08/22/19
08:03
Hot Stocks
Tabula Rasa HealthCare announces partnership with Bainbridge Health Partners »

Tabula Rasa HealthCare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

MYL

Mylan

$19.07

-0.02 (-0.10%)

, NVO

Novo Nordisk

$51.82

0.54 (1.05%)

08:02
08/22/19
08/22
08:02
08/22/19
08:02
Periodicals
Novo Nordisk sues Mylan for alleged patent infringement, Reuters reports »

Mylan (MYL) has been sued…

MYL

Mylan

$19.07

-0.02 (-0.10%)

NVO

Novo Nordisk

$51.82

0.54 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 25

    Sep

TREX

Trex Company

$85.68

-0.085 (-0.10%)

08:01
08/22/19
08/22
08:01
08/22/19
08:01
Initiation
Trex Company initiated  »

Trex Company initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 13

    Nov

AFL

Aflac

$48.98

-2.88 (-5.55%)

08:00
08/22/19
08/22
08:00
08/22/19
08:00
Hot Stocks
Aflac says not anticipating any disruption in long-term JPH Alliance plans »

Aflac said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDD

Pinduoduo

$30.14

4.165 (16.04%)

08:00
08/22/19
08/22
08:00
08/22/19
08:00
Options
Pinduoduo call buyer realizes 21% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:00
08/22/19
08/22
08:00
08/22/19
08:00
General news
Treasury Market Outlook: yields are higher »

Treasury Market Outlook:…

AFL

Aflac

$48.98

-2.88 (-5.55%)

07:59
08/22/19
08/22
07:59
08/22/19
07:59
Hot Stocks
Aflac says 'rigorous, voluntary review' of postal channel sales began in July »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:53
08/22/19
08/22
07:53
08/22/19
07:53
Conference/Events
Citigroup to hold a forum »

Citi-REITAS-SGX C-Suite…

JEC

Jacobs Engineering

$86.06

2.45 (2.93%)

07:51
08/22/19
08/22
07:51
08/22/19
07:51
Hot Stocks
Jacobs Engineering appointed as smart meter specialist in Singapore »

Jacobs has been appointed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSGN

MSG Networks

$14.78

-2.07 (-12.28%)

07:51
08/22/19
08/22
07:51
08/22/19
07:51
Recommendations
MSG Networks analyst commentary  »

MSG Networks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CERN

Cerner

$71.77

0.44 (0.62%)

07:50
08/22/19
08/22
07:50
08/22/19
07:50
Upgrade
Cerner rating change  »

Cerner upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

ADMA

ADMA Biologics

$4.05

-0.01 (-0.25%)

07:50
08/22/19
08/22
07:50
08/22/19
07:50
Hot Stocks
ADMA Biologics announces commercial relaunch of BIVIGAM »

ADMA Biologics announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

FLWS

1-800-Flowers.com

$19.36

0.74 (3.97%)

07:48
08/22/19
08/22
07:48
08/22/19
07:48
Earnings
1-800-Flowers.com sees FY20 EPS up 8%-10% »

Sees FY20 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 25

    Sep

FLWS

1-800-Flowers.com

$19.36

0.74 (3.97%)

07:48
08/22/19
08/22
07:48
08/22/19
07:48
Earnings
1-800-Flowers.com reports Q4 adj. EPS (12c), consensus (14c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 25

    Sep

SQM

SQM

$25.40

-0.86 (-3.27%)

07:45
08/22/19
08/22
07:45
08/22/19
07:45
Downgrade
SQM rating change  »

SQM downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

SEDG

SolarEdge

$87.87

3.16 (3.73%)

07:44
08/22/19
08/22
07:44
08/22/19
07:44
Downgrade
SolarEdge rating change  »

SolarEdge downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIF

Tiffany

$84.51

2.27 (2.76%)

07:43
08/22/19
08/22
07:43
08/22/19
07:43
Recommendations
Tiffany analyst commentary  »

Tiffany price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

DKS

Dick's Sporting

$32.97

0.62 (1.92%)

07:42
08/22/19
08/22
07:42
08/22/19
07:42
Hot Stocks
Dick's Sporting reports Q2 eCommerce sales up 21% »

eCommerce penetration for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

FLR

Fluor

$17.35

0.3 (1.76%)

07:41
08/22/19
08/22
07:41
08/22/19
07:41
Upgrade
Fluor rating change  »

Fluor upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DKS

Dick's Sporting

$32.97

0.62 (1.92%)

07:40
08/22/19
08/22
07:40
08/22/19
07:40
Hot Stocks
Dick's Sporting up 10% after Q2 results beat estimates, FY19 profit view raised »

In pre-market trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.